Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/d3/44/ca/d344ca39-4992-6f81-e25f-f9760c72db0f/mza_9022225513546609814.jpg/600x600bb.jpg

DirectorsTalk Interviews

Giles Arbor

107 episodes

3 days ago

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.

Investing

Business

RSS

All content for DirectorsTalk Interviews is the property of Giles Arbor and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Investing

Business

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/42928420/42928420-1738051971612-9069a08c6228.jpg

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic

DirectorsTalk Interviews

14 minutes 31 seconds

1 month ago

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic

Cizzle Biotechnology (LON:CIZ) is rolling out its lung cancer test across North America. With 14.5M people needing screening, and contracts now live with OmniHealth & Moffitt Cancer Center, Dr Allan Syms outlines the road to revenue.

#CizzleBiotech #LungCancer #BiotechInvesting #LifeSciences #Diagnostics #EarlyDetection #HealthTech #AIMstocks #CIZ1B #OmniHealth #CizzleBio

Cizzle Biotechnology is a UK-based diagnostics company developing a simple blood test for the early detection of lung cancer. Its proprietary test targets the CIZ1B biomarker to identify the disease at a stage where treatment outcomes are significantly improved.